Journal Mobile Options
Table of Contents
Vol. 19, No. 1, 2005
Issue release date: December 2004
Section title: Original Research Article
Dement Geriatr Cogn Disord 2005;19:51–56

A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease

Karaman Y.a · Erdoğan F.a · Köseoğlu E.a · Turan T.b · Ersoy A.Ö.a
Departments of aNeurology and bPsychiatry, Medical Faculty, Erciyes University, Kayseri, Turkey
email Corresponding Author

Füsun Erdoğan

Erciyes University, Medical Faculty

Neurology Department

TR–38039 Kayseri (Turkey)

Tel. +90 352 4374901, Fax +90 352 4375285, E-Mail


  1. Blass JP: Pathophysiology of Alzheimer’s syndrome. Neurology 1993;43(suppl 4):S25–S38.
  2. Gauthier S: Clinical Diagnosis and Management of Alzheimer’s Disease. London, Martin Duniz Ltd, 1999, pp 57–67, 249–269.
  3. Davis KL, Haroutunian V: Strategies for the treatment of Alzheimer’s disease. Neurology 1993;43(suppl 4):S52–S55.
  4. Engelborghs S, Deyn PP: The neurochemistry of Alzheimer’s disease. Acta Neurol Belg 1997;97:67–84.
  5. Selkoe DJ: The molecular pathology of Alzheimer’s disease. Neuron 1991;6:487–498.
  6. Sands LP, Katz I, Schneider L: Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 1999;13:26–34.
  7. Sarter M, Bruno JP: Cognitive functions of cortical acetylcholine. Brain Res Brain Res Rev 1997;23:28–46.
  8. Sirvio J: Strategies that support declining cholinergic neurotransmission in Alzheimer’s disease patients. Gerontology 1999;45(suppl 1):3–14.
    External Resources
  9. Hogan DB, Patterson C: Treatment of Alzheimer’s disease and other dementias – Review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 2002;29:306–314.
  10. Taylor P: Development of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease. Neurology 1998;51(suppl 1):S30–S35.
  11. Knopman D, Morris JC: An update on primary therapies for Alzheimer’s disease. Arch Neurol 1997;54:1406–1409.
  12. Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS: Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: Double blind trial. BMJ 1994;308:879–883.
  13. Cummings JL, Vinters HV, Cole GM, et al: Alzheimer’s disease. Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51(suppl 1):S2–S17.
  14. Doody RS, Stevens JC, Beck C, et al: Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–1166.
  15. Weinstock M: Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 1999;12:307–323.
  16. Anand R, Messina J, Hartman R: Dose response effect of rivastigmine in the treatment of Alzheimer’s disease. Int J Geriatr Psychopharmacol 2002;2:68–72.
  17. Cutler ND, Polinsky RJ, Sramek JJ, et al: Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol Scand 1998;97:244–250.
  18. Farlow M, Anand R, Messina JA, Hartman R, Veach J: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2001;46:110.
  19. Spencer CM, Noble S; Rivastigmine. Drug Aging 1998;13:391–411.
  20. Ballard CG: Advances in the treatment of Alzheimer’s disease: Benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64–70.
  21. Roe CM, Anderson MJ, Spivack B: Use of anticholinergic medication by older adults with dementia. J Am Geriatr Soc 2002;50:836–842.
  22. Giacobini E, Spiegel R, Enz A: Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: Correlation with cognitive benefit. J Neural Transm 2002;109:1053–1065.
  23. Corey-Bloom J, Anand R, Veach J: ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate): A new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1:55–65.
  24. Darreh-Shori T, Almkvist O, Guan ZZ, et al: Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563–572.
  25. Rosler M, Anand R, Cicin-Sain A: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trial. BMJ 1999;318:633–638.
  26. Williams BR, Nazarians A, Gill MA: A review of rivastigmine: A reversible cholinesterase inhibitor. Clin Ther 2003;25:1634–1653.
  27. McKeith I, DelSer T, Emre M, et al: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
  28. Moretti R, Torre P, Antonello RM, et al: Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;361–363.
  29. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  30. Mc Khann G, DrachmanD, Folstein M, Katzman R, Price D, et al: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  31. Folstein MF, Hug PR, Folstein SE: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–192.
  32. Rosen WG, Mohs RC, Davis KL: A new rating scala for assessing demented patients. Am J Psychiatry 1984;141:1356–1364.
  33. Schneider LS, Olin JT, Doody RS: Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11:22–32.
  34. Gelinas I, Gauthier L, Mclntryne M, Gauthier S: Development of a functional measure for persons with Alzheimer’s disease: The disability assessment for dementia. Am J Occup Ther 1999;53:471–481.
  35. Galasko D, Bennett D, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:33–39.
  36. Dejong R, Osterland OW, Roy GW: Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther 1989;11:545–554.
  37. Reisberg B, Ferris SH, de Leon MJ, et al: Global deterioration scale (GDS). Psychopharmacol Bull 1988;24:661–663.
  38. Feldman H, Sauter A, Donald A, Gelinas I Gauthier S, et al: The Disability Assessment for Dementia Scale: A 12-month study of functional ability in mild to moderate severity Alzheimer’s disease. Alzheimer Dis Assoc Disord 2001;15:89–95.
  39. Grossberg GT, Stahelin HB, Messina JC, Anand R: Lack of adverse pharmacodynamic drug interactions with rivastigmine and 22 classes of medication. Int J Geriatr Psychiatry 2000;15:242–247.
  40. Doraiswamy M, Hartman R, Graham S: Early intervention with a cholinesterase inhibitor produces long-term beneficial effects in moderately severe AD patients. Neurobiol Aging 2000;21:275.
    External Resources
  41. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417–422.
  42. Potki SG, Anand R, Hartman R, Veach J, Grossberg G: Impact of Alzheimer’s disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:713–720.
  43. Desai A, Grossberg G: Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders. Eur Neurol 2000;44:236–241.
  44. Forette F, Anand R, Gharabowi G: A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine. Eur J Neurol 1999;6:423–429.